Drug name - Zydelig
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44638 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Aug, 2025
(2 years from now) | |
| US8865730 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(10 years from now) | |
| US10730879 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(10 years from now) | |
| US9469643 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Sep, 2033
(10 years from now) | |
| CN102229609A | GILEAD SCIENCES INC | Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta |
Mar, 2013
(9 years ago) | |
| CN104334560A | GILEAD SCIENCES INC | (S) -2-(1 - (9H - -6 - Ylamino) Propyl) -5--3 - Phenyl - -4 (3H) - Ketone Of Polymorph |
Mar, 2017
(5 years ago) | |
| CN106146506A | GILEAD SCIENCES INC | Polymorph Of (S)-2-(1-(9H-Purine-6-Ylamino)Propyl)-5-Fluorin-3-Phenyl Quinazoline-4(3H) Ketone |
Apr, 2018
(4 years ago) | |
| CN101031569B | GILEAD SCIENCES INC | As Human Phosphatidylinositol 3- Delta Inhibitor Quinazolinone |
May, 2025
(2 years from now) | |
| CN101031569A | GILEAD SCIENCES INC | Quinazolones As Human Phosphoinositide 3-Kinase Delta Inhibitor |
May, 2025
(2 years from now) | |
| EP2612862A3 | GILEAD SCIENCES INC | Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta |
May, 2025
(2 years from now) | |
| EP2612862A2 | GILEAD SCIENCES INC | Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta |
May, 2025
(2 years from now) | |
| EP3153514A1 | GILEAD SCIENCES INC | Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta |
May, 2025
(2 years from now) | |
| EP2612862B1 | GILEAD SCIENCES INC | Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta |
May, 2025
(2 years from now) | |
| EP3153514B1 | GILEAD SCIENCES INC | Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta |
May, 2025
(2 years from now) | |
| EP1761540A1 | GILEAD SCIENCES INC | Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta |
May, 2025
(2 years from now) | |
| EP1761540B1 | GILEAD SCIENCES INC | Quinazolinones As Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta |
May, 2025
(2 years from now) | |
| EP2834241B1 | GILEAD SCIENCES INC | Polymorphic Forms Of (S)-2-(1-(9H-Purin-6-Ylamino)Propyl)-5-Fluoro-3-Phenylquinazolin-4(3H)-One |
Mar, 2033
(10 years from now) | |
| EP2834241A1 | GILEAD SCIENCES INC | Polymorphic Forms Of (S)-2-(1-(9H-Purin-6-Ylamino)Propyl)-5-Fluoro-3-Phenylquinazolin-4(3H)-One |
Mar, 2033
(10 years from now) | |
| EP2834241A4 | GILEAD SCIENCES INC | Polymorphic Forms Of (S)-2-(1-(9H-Purin-6-Ylamino)Propyl)-5-Fluoro-3-Phenylquinazolin-4(3H)-One |
Mar, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980901 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta |
May, 2025
(2 years from now) | |
| US9149477 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta |
May, 2025
(2 years from now) | |
| USRE44599 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Jul, 2025
(2 years from now) | |
| US9492449 | GILEAD SCIENCES INC | Therapies for hematologic malignancies |
Mar, 2030
(7 years from now) | |
Drugs and Companies using IDELALISIB ingredient
Treatment: For the treatment of patients with cll, fl, or sll; Inhibition on pi3k kinase; For the treatment of patients with cll, fl, or sll; for the treatment of patients with relapsed follicular b-cell non-hodgkin lymphoma or [relapsed] small lymphocytic lymphoma; In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll)
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG | TABLET;ORAL | Prescription |
| 150MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.